Home » OPTIMER INITIATES CLINICAL TRIALS OF OPT-99 FOR GASTROENTERITIS
OPTIMER INITIATES CLINICAL TRIALS OF OPT-99 FOR GASTROENTERITIS
Phase III
clinical trials of Optimer's OPT-99 for bacterial gastroenteritis are scheduled
to begin in May 2006, the company has announced. The company plans to develop
OPT-99 for the treatment of bacterial gastroenteritis including traveler's diarrhea.
Optimer will conduct two independent, international Phase III trials.
Investigators will begin to enroll patients in mid-May 2006 in the U.S., Mexico,
and Peru; the second trial will soon follow in India and Africa.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May